BillionToOne, Inc. (BLLN)
| Market Cap | 2.29B |
| Revenue (ttm) | 209.03M |
| Net Income (ttm) | -30.62M |
| Shares Out | 44.02M |
| EPS (ttm) | -0.70 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About BLLN
BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. Our superior technology platform has enabled us to build category-defining prenatal and oncology products. Our products reveal actionable insights from a simple blood draw that are fundamentally changing how diseases are diagnosed and treated, leading to a paradigm shift in personalized ... [Read more]
News
BillionToOne targets over $2 billion valuation in US IPO
Molecular diagnostics firm BillionToOne said on Friday it was aiming at a valuation of up to $2.42 billion in its U.S. initial public offering.
BillionToOne Launches IPO In Slowing IPO Market
BillionToOne, Inc. is rapidly growing in the prenatal and oncology diagnostics sectors, nearing operating breakeven, and has filed for a $100 million IPO. BLLN's revenue is driven mainly by its UNITY ...
U.S. IPO Weekly Recap: 6 IPOs Debut, Pipeline Grows, Despite Government Shutdown
Six IPOs debuted this week, while two SPACs listed. Thirteen IPOs and five SPACs also submitted initial filings. No traditional IPOs are currently scheduled for the week ahead as the government shutdo...
Molecular diagnostics firm BillionToOne files for US IPO
BillionToOne filed for an initial public offering in the United States on Tuesday.
BillionToOne IPO Registration Document (S-1)
BillionToOne has filed to go public with an IPO on the NASDAQ.